Fig. 6.

Oral BSI-401 and oxaliplatin cooperate in vivo to inhibit COLO357FG pancreatic tumor growth. Forty athymic mice bearing orthotopic COLO357FG pancreatic tumors were randomly allocated (n= 5) to be treated with BSI-401 400 mpk, po QD5+R2×4, oxaliplatin 10 mpk ip, QW×4 as indicated, their combination, or their respective po and ip vehicle as control. A,B, Tumor volume following treatment, quantified as the sum of all detected photons within the region of the tumor per second. Means and SE are shown. * P< 0.05 combination versus control by one-way analysis of variance and Dunnett’s multiple comparison post test; C, Mice were sacrificed by carbon dioxide inhalation when evidence of advanced bulky disease was present. The day of sacrifice was considered the day of death for survival evaluation. BSI-401 prevents oxaliplatin-induced acute cold allodynia. D, Paw withdrawal latency on days 0 and 6 following treatment. Twelve rats were randomly allocated to receive a single administration of 200 mg/kg of ip BSI-401, 5 mg/kg of ip oxaliplatin, both, or their respective ip vehicle as control. The latency for cold pain hind paw withdrawal was measured on days 0 and 6. Means and SE are shown. * P< 0.05 treatment versus control by one-way analysis of variance and Dunnett’s multiple comparison post test.